Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562319 | 0.98 | LMNA (0.55) | LMNAPARP10PARP15SLC1A3SLC1A2 | |
| SCHEMBL8396762 | 0.98 | LMNA (0.55) | LMNAPARP10PARP15SLC1A3SLC1A2 | |
| SCHEMBL561524 | 0.95 | — | — | |
| SCHEMBL30427433 | 0.90 | PARP15 (0.42) | LMNAPARP10PARP15SLC1A3SLC1A2 | |
| SCHEMBL111361 | 0.90 | — | — | |
| Acetic Acid SCHEMBL4306790 | 0.90 | LMNA (0.53) | LMNAPARP10PARP15SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL28974199 | 0.88 | — | — | |
| SCHEMBL21029278 | 0.82 | LMNA (0.39) | LMNAPARP10PARP15SLC1A3SLC1A2 | |
| SCHEMBL5861626 | 0.82 | LMNA (0.48) | LMNAPARP10PARP15SLC1A3SLC1A2 | |
| SCHEMBL2633967 | 0.82 | PARP15 (0.38) | LMNAPARP10PARP15SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619204-B1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2022-12-01 | — | — | US | disclosed |
| US-10596154-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-03-24 | — | — | US | disclosed |
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | THE UNIVERSITY OF MELBOURNE (AU) | 2020-03-12 | — | — | US | disclosed |
| EP-3619204-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | The University of Melbourne (AU) | 2020-03-11 | — | — | EP | disclosed |
| CN-110753688-A | Compounds for the treatment of respiratory diseases | 墨尔本大学 | 2020-02-04 | — | — | CN | disclosed |
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-04-25 | — | — | US | disclosed |
| US-10131677-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180325910-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-11-15 | — | — | US | disclosed |
| WO-2018201192-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | THE UNIVERSITY OF MELBOURNE (AU) | 2018-11-08 | — | — | WO | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1673385-A4 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INT (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1673385-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | Boehringer Ingelheim International GmbH (DE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1654261-A1 | HEPATITIS C INHIBITOR COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| US-20050080005-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-14 | — | — | US | disclosed |
| WO-2005028501-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| US-20050020503-A1 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | LMNA 2964/4885PARP10 1302/4885PARP15 387/4885 |
| US-10596154-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | LMNA 2378/4885PARP10 1523/4885PARP15 494/4885 |
| US-10131677-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | LMNA 2964/4885PARP10 1302/4885PARP15 387/4885 |
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | LMNA 1444/4885PARP10 2679/4885PARP15 2509/4885 |
| US-20050020503-A1 | Hepatitis C inhibitor compounds | HAVCR2, CTRL, CTRC | LMNA 816/4885PARP10 1314/4885PARP15 3473/4885 |
| US-20200079757-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | LMNA 1444/4885PARP10 2679/4885PARP15 2509/4885 |
| US-20180325910-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | LMNA 2571/4885PARP10 1520/4885PARP15 465/4885 |
| US-20050080005-A1 | Macrocyclic peptides active against the hepatitis C virus | CTRL, RPP30, RNASE1 | LMNA 2550/4885PARP10 1858/4885PARP15 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.